Illumina shareholders re-elect eight of nine Illumina directors

26 May 2023 | Friday | News

Illumina announces preliminary results of annual meeting
Image Source | Public Domain

Image Source | Public Domain

Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that based on the preliminary results of its 2023 Annual Meeting, Illumina shareholders have voted to elect eight of nine Illumina director nominees – Francis deSouza, Robert Epstein, MD, Frances Arnold, PhD, Caroline Dorsa, Scott Gottlieb, MD, Gary Guthart, PhD, Philip Schiller, and Sue Siegel, as well as Andrew Teno, to the Board of Directors. The Board thanks John Thompson for his board tenure and extraordinary leadership.

Illumina issued the following statement:

"Illumina thanks shareholders for their continued support of the company, which remains committed to its mission of improving human health by unlocking the power of the genome. We appreciate the constructive shareholder feedback throughout this process and are committed to delivering on our plan to accelerate shareholder value creation. We will continue to provide transparent and effective communication as we move forward together.

We would like to welcome Andrew Teno, a portfolio manager at Icahn Capital LP, to the Board and look forward to productive and collaborative engagement.

We also thank John Thompson for his years of service and contributions to Illumina as Chair of the Board. His deep executive experience and business knowledge were greatly valued during his tenure. John brought extensive technology leadership, including as a CEO at Symantec and Virtual Instruments, and Chairman of the Board at Microsoft, to Illumina. His depth and breadth of knowledge in technology and across a number of private and public sectors, as well as his financial expertise, greatly contributed to the Board's strategic leadership of the company."

The company also noted that shareholders approved the proposal to ratify auditors, one-year frequency on say-on-pay, and the stock incentive plan proposal; and shareholders did not approve the company's say-on-pay proposal.  

The results announced today are considered preliminary and are subject to certification by the independent Inspector of Elections. The final certified results are expected to be provided in a Current Report filed on Form 8-K with the U.S. Securities and Exchange Commission within the next four business days.

 

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close